Concourse Financial Group Securities, Inc. Cybin Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$0.26 - $0.46 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.3 - $0.46 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.38 - $0.65 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.29 - $0.63 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.29 - $0.63 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.23 - $0.39 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.3 - $0.56 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.26 - $0.64 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.48 - $1.11 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.41 - $0.88 $0 - $0
Q1 2022 May 09, 2022	BUY	$0.74 - $1.22 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$1.13 - $2.31 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$1.83 - $3.18 $0 - $0

Others Institutions Holding CYBN

# of Institutions

Shares Held

66.1K

Call Options Held

Put Options Held

View Full List

About CYBIN INC.

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $1.58B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

More about CYBN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account